These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 3118583)

  • 1. Chronic experimental diabetes accelerates urinary elimination of deprenyl and its metabolites.
    Adeghate E; Sótonyi P; Kalász H
    Open Med Chem J; 2008 Jan; 2():1-5. PubMed ID: 19662137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-deprenyl: pharmacological spectrum of its activity.
    Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
    Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration and putative protection in Parkinsonism.
    Archer T; Fredriksson A
    Neurotox Res; 2000; 2(2-3):251-92. PubMed ID: 16787845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of selegiline on antioxidant systems in the nigrostriatum in rat.
    Takahata K; Shimazu S; Katsuki H; Yoneda F; Akaike A
    J Neural Transm (Vienna); 2006 Feb; 113(2):151-8. PubMed ID: 15959853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of deprenyl enantiomers.
    Szökö E; Kalász H; Magyar K
    Eur J Drug Metab Pharmacokinet; 1999; 24(4):315-9. PubMed ID: 10892894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
    Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
    Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.
    Fredriksson A; Archer T
    J Neural Transm Gen Sect; 1995; 102(1):19-34. PubMed ID: 8785021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences.
    Yoshida T; Oguro T; Kuroiwa Y
    Xenobiotica; 1987 Aug; 17(8):957-63. PubMed ID: 3118583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
    Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
    Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic aspects of deprenyl effects.
    Magyar K; Tóthfalusi L
    Pol J Pharmacol Pharm; 1984; 36(4):373-84. PubMed ID: 6441926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    Engberg G; Elebring T; Nissbrandt H
    J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.